152 related articles for article (PubMed ID: 36442805)
21. Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy.
Hemetsberger R; Richardt G; Lahu S; Valina C; Menichelli M; Abdelghani M; Wöhrle J; Toelg R; Witzenbichler B; Mankerious N; Liebetrau C; Bernlochner I; Hamm CW; Allali A; Joner M; Fusaro M; Xhepa E; Hapfelmeier A; Kufner S; Sager HB; Schüpke S; Laugwitz KL; Schunkert H; Neumann FJ; Kastrati A; Cassese S
Cardiovasc Revasc Med; 2022 Aug; 41():122-128. PubMed ID: 35045943
[TBL] [Abstract][Full Text] [Related]
22. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
Cardiovasc Drugs Ther; 2021 Jun; 35(3):561-574. PubMed ID: 32816142
[TBL] [Abstract][Full Text] [Related]
23. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
[TBL] [Abstract][Full Text] [Related]
24. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus.
Ndrepepa G; Kastrati A; Menichelli M; Neumann FJ; Wöhrle J; Bernlochner I; Richardt G; Witzenbichler B; Sibbing D; Gewalt S; Angiolillo DJ; Hamm CW; Hapfelmeier A; Trenk D; Laugwitz KL; Schunkert H; Schüpke S; Mayer K
JACC Cardiovasc Interv; 2020 Oct; 13(19):2238-2247. PubMed ID: 33032712
[TBL] [Abstract][Full Text] [Related]
25. Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.
Coughlan JJ; Aytekin A; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Gewalt S; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Müller A; Kufner S; Liebetrau C; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Fusaro M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A
JAMA Cardiol; 2021 Oct; 6(10):1121-1129. PubMed ID: 34190967
[TBL] [Abstract][Full Text] [Related]
26. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
27. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI.
Conrotto F; Bertaina M; Raposeiras-Roubin S; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores Blanco P; Garay A; Quadri G; Varbella F; Caneiro Queija B; Cobas Paz R; Cespón Fernández M; Muñoz Pousa I; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Abu-Assi E; D'Ascenzo F
Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):536-542. PubMed ID: 30270638
[TBL] [Abstract][Full Text] [Related]
28. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome.
Raposeiras-Roubín S; Caneiro Queija B; D'Ascenzo F; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores Blanco P; Garay A; Varbella F; Tomassini F; Cobas Paz R; Cespón Fernández M; Muñoz Pousa I; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Baz-Alonso JA; Calvo-Iglesias F; Valdés M; Cequier Á; Gaita F; Alexopoulos D; Íñiguez-Romo A; Abu-Assi E
Rev Esp Cardiol (Engl Ed); 2019 Mar; 72(3):215-223. PubMed ID: 30029980
[TBL] [Abstract][Full Text] [Related]
30. P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
Sachdeva A; Mutyala R; Mantri N; Zhu S; McNulty E; Solomon M
J Interv Cardiol; 2023; 2023():1147352. PubMed ID: 37251366
[TBL] [Abstract][Full Text] [Related]
31. Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry.
Al Raisi S; Protty M; Raposeiras-Roubín S; D'Ascenzo F; Abu-Assi E; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores-Blanco P; Varbella F; Cespón-Fernández M; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Cequier Á; Gaita F; Alexopoulos D; Valgimigli M; Íñiguez-Romo A; Kinnaird T
Minerva Cardiol Angiol; 2021 Aug; 69(4):408-416. PubMed ID: 34137238
[TBL] [Abstract][Full Text] [Related]
32. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
33. Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry.
D'Ascenzo F; Elia E; de Filippo O; Manai R; Breviario S; Bruno F; Iannaccone M; Wańha W; Bianco M; Patti G; Raposeiras-Roubin S; Abu-Assi E; Bo M; De Ferrari GM; Conrotto F;
Int J Cardiol; 2022 Apr; 353():9-14. PubMed ID: 35090983
[TBL] [Abstract][Full Text] [Related]
34. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
35. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'.
Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW
Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis.
Dawwas GK; Dietrich E; Winchester DE; Winterstein AG; Segal R; Park H
Pharmacotherapy; 2019 Sep; 39(9):912-920. PubMed ID: 31332815
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
[TBL] [Abstract][Full Text] [Related]
38. Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.
Orban M; Kleeberger J; Ouarrak T; Freund A; Feistritzer HJ; Fuernau G; Geisler T; Huber K; Dudek D; Noc M; Montalescot G; Neumer A; Haller P; Clemmensen P; Zeymer U; Desch S; Massberg S; Schneider S; Thiele H; Hausleiter J
Clin Res Cardiol; 2021 Sep; 110(9):1493-1503. PubMed ID: 33999281
[TBL] [Abstract][Full Text] [Related]
39. Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Valina C; Neumann FJ; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Aytekin A; Richardt G; Witzenbichler B; Sibbing D; Cassese S; Angiolillo DJ; Kufner S; Liebetrau C; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Wustrow I; Joner M; Trenk D; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
J Am Coll Cardiol; 2020 Nov; 76(21):2436-2446. PubMed ID: 33213722
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and safety of oral P2Y
Farmakis IT; Zafeiropoulos S; Doundoulakis I; Pagiantza A; Karagiannidis E; Moysidis DV; Stalikas N; Kassimis G; Michalis LK; Karvounis H; Giannakoulas G
Open Heart; 2022 Apr; 9(1):. PubMed ID: 35428703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
